Company news: Forest Labs, Novartis and Pfizer

Share this article:
Forest Labs said its CEO will challenge a US Department of Health and Human Services attempt to exclude him from participation in federal healthcare programs. HHS notified CEO Howard Solomon of the potential action yesterday by letter, the company said, adding that the missive alleges no wrongdoing and stems from matters the company settled last year. In September Forest paid $313 million and agreed to plead guilty to a felony obstruction of justice charge, and two misdemeanor counts related to the distribution of an unapproved drug—Levothroid—and the misbranding or off-label promotion of two anti-depressants, Lexapro and Celexa. Solomon, who was given 30 days to respond to HHS, would have to step down from his present executive positions if the HHS decides to exercise its exclusion authority.

An FDA advisory panel voted in favor of approving drugs from Pfizer and Novartis for pancreatic neuroendocrine tumors (pNET). The drugs, Afinitor from Novartis and Sutent from Pfizer, are already on the market for treating kidney cancer. Regulatory decisions on the pNET indications are likely to come in late 2011.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.